AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Celcuity Stock Hits All-Time High on Gedatolisib Trial Success
ByAinvest
Friday, Aug 15, 2025 12:43 pm ET1min read
Celcuity's stock has reached an all-time high of $53.85, driven by positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial for its lead drug candidate, Gedatolisib. The trial showed a reduction in risk of disease progression or death and an incremental improvement in progression-free survival for HR+/HER2-advanced breast cancer patients. The PIK3CA mutant cohort is enrolling participants, with topline data expected by year-end. Another phase III trial, VIKTORIA-2, is also ongoing.
Celcuity Inc. (CELC) saw its stock price hit an all-time high of $53.85 today, fueled by the positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. The trial, which evaluated Gedatolisib in combination with fulvestrant and palbociclib for HR+/HER2-advanced breast cancer, demonstrated a significant reduction in risk of disease progression or death and an incremental improvement in progression-free survival [1].The PIK3CA wild-type cohort showed a 76% reduction in disease progression risk with the gedatolisib triplet therapy and a 67% reduction with the doublet therapy. This represents a potential paradigm shift in HR+/HER2- advanced breast cancer treatment, with hazard ratios (HR) of 0.24 and 0.33, respectively [2].
The PIK3CA mutant cohort is currently enrolling participants, with topline data expected by the end of 2025. Additionally, another phase III trial, VIKTORIA-2, is ongoing, evaluating the efficacy and safety of Gedatolisib in combination with fulvestrant and CDK4/6 inhibitors as a first-line treatment for endocrine therapy-resistant HR+/HER2- advanced breast cancer patients.
Celcuity's stock has seen a substantial increase, reflecting a gain of over 300% from its price of $12.60 in December 2024. The company's strong financial position, with a proforma cash position of $455 million, provides flexibility for the critical transition from development to commercialization [2].
References:
[1] https://www.rttnews.com/3566617/celcuity-stock-hits-all-time-high-on-gedatolisib-progress.aspx
[2] https://www.stocktitan.net/news/CELC/celcuity-inc-reports-second-quarter-2025-financial-results-and-kuvlwcp6udhp.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet